Evidence map›Paper›PMID 42666080›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Early Retinal UCHL1 Dysregulation Coupled With Synaptic Loss Reflects Alzheimer's Disease Severity.

Altan Rentsendorj, Jean-Philippe Vit, Alexandre Hutton, Yosef Koronyo, Saba Shahin, Edward Robinson, Ernesto Barron, Anthony Rodriguez, Ousman Jallow, Julia Sheyn and 16 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

26 authors.

Altan RentsendorjDepartment of Neurosurgery, Maxine Dunitz Neurosurgical Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Jean-Philippe VitDepartment of Neurosurgery, Maxine Dunitz Neurosurgical Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Alexandre HuttonDepartment of Computational Biomedicine, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Yosef KoronyoDepartment of Neurosurgery, Maxine Dunitz Neurosurgical Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Saba ShahinDepartment of Neurosurgery, Maxine Dunitz Neurosurgical Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Edward RobinsonDepartment of Neurosurgery, Maxine Dunitz Neurosurgical Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Ernesto BarronDoheny Eye Institute, University of California, Los Angeles, California, USA.
Anthony RodriguezDoheny Eye Institute, University of California, Los Angeles, California, USA.
Ousman JallowDepartment of Neurosurgery, Maxine Dunitz Neurosurgical Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Julia SheynBoard of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Bhakta Prasad GaireDepartment of Neurosurgery, Maxine Dunitz Neurosurgical Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Lalita SubediDivision of Infectious Diseases and Immunology, Department of Pediatrics, Guerin Children's at Cedars-Sinai Medical Center, Los Angeles, California, USA.
Miyah R DavisDepartment of Neurosurgery, Maxine Dunitz Neurosurgical Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Barathan GnanabharathiBoard of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Alexander V LjubimovBoard of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Stuart L GrahamMacquarie Medical School, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, NSW, Australia.
Vivek K GuptaMacquarie Medical School, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, NSW, Australia.
Mehdi MirzaeiMacquarie Medical School, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, NSW, Australia.
Debra HawesDepartment of Pathology, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
Katlin SilmBoard of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Keith L BlackDepartment of Neurosurgery, Maxine Dunitz Neurosurgical Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Lon S SchneiderDepartment of Psychiatry and The Behavioral Sciences, Department of Neurology, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
Alfredo A SadunDoheny Eye Institute, University of California, Los Angeles, California, USA.
Jesse G MeyerDepartment of Computational Biomedicine, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Dieu-Trang FuchsDepartment of Neurosurgery, Maxine Dunitz Neurosurgical Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Maya Koronyo-HamaouiDepartment of Neurosurgery, Maxine Dunitz Neurosurgical Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.ORCID https://orcid.org/0000-0003-2864-8442

Funding

Alzheimer's Disease Hallmark Pathology and Associated Inflammation in the RetinaR01AG055865 · NIA · CEDARS-SINAI MEDICAL CENTER · PI Maya Koronyo-Hamaoui · 2018 to 2026
$4.9M
Retinal Imaging of Alzheimer's Disease PathologyR01AG056478 · NIA · CEDARS-SINAI MEDICAL CENTER · PI KORONYO-HAMAOUI, MAYA · 2017 to 2021
$2.5M
Democratizing Multi-Omics to Expedite Discovery of Hidden Metabolic PathwaysR35GM142502 · NIGMS · MEDICAL COLLEGE OF WISCONSIN · PI MEYER, JESSE · 2021 to 2025
$2.2M
NIA NIH HHS AG056478-04S1NIA NIH HHS R01 AG055865NIA NIH HHS R01AG055865NIA NIH HHS R01 AG056478NIA NIH HHS R01AG056478NIGMS NIH HHS R35 GM142502NIGMS NIH HHS R35GM142502NIH HHSthe Gordon Foundationthe Hertz Innovation Fundsthe Ray Charles Foundationthe Saban Foundationthe Wilstein Foundation
6 · The paper itself

Abstract

Synaptic dysfunction is a major driver of cognitive decline in Alzheimer's disease (AD), yet its extent and molecular basis in the retina remain poorly defined. We integrated postmortem retinal and matched brain histopathology with ultrastructural, proteomic, biochemical, and machine-learning analyses across cognitively normal, mild cognitive impairment, and AD cohorts. Retinal glutamatergic synapses exhibited early, progressive degeneration, marked by loss of presynaptic vesicular glutamate transporter 1 (VGLUT1) and synaptophysin and postsynaptic density protein 95 (PSD95) and N-methyl-D-aspartate receptor subunit 2A (NMDAR2A), along with ribbon synapse ultrastructural disruption. Synaptic deficits correlated with amyloid-β

Indexed as

dementiaexcitatory synapseMCIN‐methyl‐D‐aspartate receptor subunit 2Ap75NTRpostsynaptic density protein 95ubiquitin–proteasome systemvesicular glutamate transporter 1

Identifiers

PMID42666080
PMCPMC13525425

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.